Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325364 · ClinicalTrials.gov registry record · Phase 3
Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 415
- Enrollment target
NCT00325364 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 415 participants.
The verdict
NCT00325364, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 415 participants
- Enrollment target
Study Summary
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 2 diabetes. Patients will be treated for 24 months with a 2-month follow-up period.
Interventions
- DRUG Human Insulin Inhalation Powder
- DRUG Injectable insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325364
The ClinicalTrials.gov registry entry for NCT00325364 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Human Insulin Inhalation Powder is the first listed.
NCT00325364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325364 about?
NCT00325364 is a clinical study titled "Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes". This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 2 diabetes. Patients will be treated for 24 months with a 2-month follow-up period.
What is the current status of trial NCT00325364?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 415 participants. The study started on 2006-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00325364?
The interventions under investigation include: Human Insulin Inhalation Powder (DRUG), Injectable insulin (DRUG).
Who is sponsoring clinical trial NCT00325364?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.